Ace Therapeutics’ Post

Logical from what I understand about aspirin & salicylates.

Interesting news about aspirin.

We are thrilled to announce that our first-in-class, oral, once-daily systemically distributed LANCL2 agonist, NIM-1324, has demonstrated therapeutic efficacy and safety in a preclinical model of rheumatoid arthritis (RA). The study, conducted in collaboration with The NIMML Institute and presented at #Immunology2024, demonstrates NIM-1324's ability to ameliorate disease severity and decrease inflammation in RA. These findings support the continued development of NIM-1324, currently in Phase 2 clinical trials, as a potential new treatment option for RA patients. View the presentation here: https://lnkd.in/dFUZAftP    #RheumatoidArthritis #RA #ClinicalTrials #PrecisionMedicine #Immunology2024

𝐁𝐨𝐞𝐡𝐫𝐢𝐧𝐠𝐞𝐫 𝐈𝐧𝐠𝐞𝐥𝐡𝐞𝐢𝐦 𝐔𝐧𝐯𝐞𝐢𝐥𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈 𝐃𝐚𝐭𝐚 𝐟𝐨𝐫 𝐒𝐮𝐫𝐯𝐨𝐝𝐮𝐭𝐢𝐝𝐞 𝐢𝐧 𝐌𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐜 𝐃𝐲𝐬𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧-𝐀𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐞𝐝 𝐒𝐭𝐞𝐚𝐭𝐨𝐡𝐞𝐩𝐚𝐭𝐢𝐭𝐢𝐬 (𝐌𝐀𝐒𝐇) Boehringer Ingelheim Boehringer Ingelheim announced promising Phase II results for its investigational glucagon/GLP-1 receptor dual agonist, survodutide, showing significant improvements in patients with MASH. Key Results: At 48 weeks, 83% of survodutide-treated patients saw significant biopsy-proven improvement in MASH without fibrosis stage worsening, compared to 18.2% on placebo. Survodutide also demonstrated positive secondary endpoints, including reduced liver fibrosis and lower liver fat content. Carinne Brouillon Carinne Brouillon, PharmD, head of human pharma at Boehringer Ingelheim, stated that survodutide shows potential as a "best-in-class treatment" with its unique action on the glucagon receptor directly on the liver. Developed in collaboration with Zealand Pharma, survodutide is an investigational dual agonist targeting GLP-1 and glucagon receptors, aiming for enhanced efficacy compared to single-hormone agonists. Boehringer Ingelheim is advancing survodutide's development in MASH and other indications, including obesity. Phase III trials, including SYNCHRONIZE-1, SYNCHRONIZE-2, and SYNCHRONIZE-CVOT, are underway, assessing survodutide in various sub-populations of overweight or obese individuals, including those with diabetes, cardiovascular diseases, and chronic kidney disease. In June 2023, Phase II data revealed that survodutide could lead to around 20% reduction in body weight, with potential for further efficacy with longer treatment duration. #Survodutide #MASH #MetabolicHealth #ClinicalTrials #GLP1 #Glucagon #ObesityTreatment #patientcare

A NodThera drug targeting NLRP3 inflammasomes might benefit Parkinson's. Quick Facts about NodThera 🔬 Focused on NLRP3 inflammasome inhibitors 🔬 Based in the UK, Washington, and Massachusetts 🔬Small company (~11-50 employees) 🔬They just completed a Phase Ib/2a clinical trial on the NLRP3 inhibitor NT-0796. Basic Science of NLRP3 Inflammasome 🔬 Part of the innate immune system 🔬Controls the activation of caspase-1 and the secretion of proinflammatory cytokines when there is an infection or cellular damage 🔬Appears to be aberrantly activated in Parkinson's, Alzheimer's disease, atherosclerosis (hardening of arteries), and other inflammatory disorders 🔬Can be activated in many ways. We don't know them all. The Clinical Trial 🥇 Over 28 days, NT-0796 brought inflammatory markers of cerebrospinal fluid in Parkinson's patients to levels present in healthy elderly controls. 🥇 Adverse events were mild. 🥇 No serious adverse events. 🥇 The drug works for once-a-day dosing. #pharma #NodThera #parkinsonsdisease #drugdevelopment #biotech https://lnkd.in/drH9drfP

Exciting news on the glucagon/GLP-1 mechanism as Boehringer Ingelheim and Zealand's survodutide, the dual agonist, reported that it met the primary endpoint and all secondary endpoints in a Phase 2 trial. 83% of adults treated with survodutide achieved MASH improvement, compared to 18% of placebo patients. Survodutide patients also saw a significant improvements in fibrosis.   Entera, in collaboration with our partner Opko, is developing the first oxyntomodulin (glucagon/GLP-1 agonist) peptide tablets for obesity and other metabolic indications. Update on our program expected mid-2024.   https://lnkd.in/da9YREnu #obesity #mash #glp1

Novo Nordisk Advances Etavopivat to Phase III Trial for Sickle Cell Disease Novo Nordisk has received Subject Expert Committee (SEC) approval from India's Central Drug Standard Control Organization (CDSCO) to conduct Phase III clinical trials of etavopivat in the treatment of sickle cell disease (SCD). The proposed trial will evaluate the oral medication, which is a small-molecule activator of erythrocyte pyruvate kinase (PKR) that has been developed as a treatment option for SCD and other hemoglobinopathies. This approval follows Novo Nordisk's presentation of the first version of the Phase III clinical trial (protocol No. NN7535-7807) from April of this year. Etavopivat aims to ameliorate the sickling of red blood cells in SCD patients through multiple mechanisms, including increasing oxygen-hemoglobin affinity and the preservation of red blood cell membrane integrity. At OxyDial, we're extremely interested in Novo Nordisk's progress and the development of etavopivat as a new treatment for SCD. The advancement to Phase III represents a significant step towards bringing these kinds of innovative new therapies to thousands of patients living with this challenging blood disorder. We're eager to see how etavopivat can help improve disease management and quality of life for those affected by SCD worldwide. Read more: https://lnkd.in/evkA_jaV #NovoNordisk #Etavopivat #SickleCellDisease #ClinicalTrial #HematologyResearch

Boehringer Ingelheim reports on survodutide, a glucagon/GLP-1 treatment for obesity, in patients with liver disease due to MASH. Up to 83% of adults treated with survodutide achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo [18.2%] in a Phase II trial, at 48 weeks. The press release notes the ‘…glucagon agonist component in survodutide has the potential to increase energy expenditure…’ while the ‘…GLP-1 agonist component decreases appetite while increasing fullness and satiety.’ Dr. Arun Sanyal at Virginia Commonwealth University School of Medicine, and Principal Investigator of the trial was ‘…thrilled to see these statistically significant results from the Phase II trial of survodutide in MASH and fibrosis.’ Carinne Brouillon, PharmD at Boehringer Ingelheim noted the ‘…MASH results show survodutide has potential to become a best-in-class treatment, and we believe its true differentiator is the action of the glucagon receptor agonism which works directly on the liver.’ Shares of partner company Zealand Pharma rocketed by 35% this week, in what is becoming more than just a two-horse race between Eli Lilly and Company and Novo Nordisk. https://lnkd.in/eBv_nSvZ

Interested in RNA delivery systems in cardiovascular disease therapeutics? Check out our last review paper in Advanced Drug Delivery Reviews.

Medialis Ltd we continue to raise awareness of rare diseases to ensure timely diagnosis and treatment. This week’s Rare Disease Spotlight focuses on myasthenia gravis (MG).    It is a chronic rare autoimmune disease that causes weakness of the skeletal muscles. It occurs when the immune system mistakenly attacks the nervous system, often due to abnormalities of the thymus gland. Although not curative, treatments have improved in recent decades improving the daily functioning and quality of life of these patients. While it can be life-threatening in severe cases, most MG patients have a normal life expectancy. New research and applications of artificial intelligence may also hold promise for future management of the disease.    Muscular Dystrophy Association, Myasthenia Gravis Foundation of America, Inc., Autoimmune Association, The European Society for Immunodeficiencies (ESID), New Horizons Un-Limited: Disability Information & Inspiration, National Institute of Neurological Disorders and Stroke (NINDS), and Genetic and Rare Disease Network have all been providing long-standing support to patients and their families.    For more details on myasthenia gravis, have a look at our Spotlight below.   #MedicalAffairs #RareDisease #DiseaseSpotlight #MyestheniaGravis #RealWorldEvidence #RWE Alexion Pharmaceuticals, Inc., argenx, Astellas Pharma, Cartesian Therapeutics, Catalyst Pharmaceuticals, Inc., CSL Behring B.V., Genentech, GSK, Grifols, HARBOUR BIOMED, Horizon, Roche, Immunovant, The Janssen Pharmaceutical Companies of Johnson & Johnson, Momenta Pharmaceuticals, IASO BioTherapeutics（驯鹿生物）, Novartis, Ra Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Sanofi, Takeda, TERRA BIOLOGICAL LLC, UCB, Viela Bio